在医院环境中使用 gabapentin 治疗酒精戒断综合征:一个随机的开放标签受控试验
Ruth E DeFoster1, Robert J Morgan2, Jonathan G Leung3
1Division of Hospital Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Substance use & misuse
|July 20, 2023
概括
固定剂量 gabapentin 在住院酒精戒断综合征 (AWS) 患者中显示出与 benzodiazepines 类似的结果. 由于研究的局限性,需要进行进一步的研究,包括低入学率和随机化前的二甲使用.
科学领域:
- 内部医学 内部医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 患有酒精戒断综合征 (AWS) 的住院患者经常接受二.
- gabapentin 是一种有效的门诊AWS治疗,但其住院疗效较少研究.
- 有限的数据存在于加巴丁作为住院AWS患者的二胺替代品.
研究的目的:
- 为了比较固定剂量 gabapentin 与 CIWA 指导的 benzodiazepines 在住院治疗AWS.
- 评估 gabapentin 在 AWS 的住院患者环境中的疗效和安全性.
主要方法:
- 一项开放标签,随机对照试验,涉及88名患有复杂AWS (PAWSS ≥4) 风险的成年患者.
- 患者被随机分配,接受固定剂量 gabapentin 逐渐或标准 CIWA 导向的佐地平治疗.
- 主要结局是停留时间 (LOS);次要结局包括发作,惊发作,ICU转移和患者报告的症状.
主要成果:
- gabapentin 组的停留时间较短,但这种差异在统计学上并不显著.
- 在次要结局 (如发作,惊发作或ICU转移) 中没有发现显著差异.
- 虽然在统计学上没有显著性,但 gabapentin 组与 benzodiazepine 组相比,接受的 benzodiazepine 的平均量不到 benzodiazepine 的一半.
结论:
- 固定剂量 gabapentin 在轻度/中度住院AWS时提供与二类药物相似的结果.
- 研究的解释受限于两组的低注册和随机化前佐地平剂的使用.
- 加巴丁可能是一个可行的替代品,但需要进一步调查.
更多相关视频
05:40The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans
Published on: April 28, 2022
3.1K
08:05A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers
Published on: January 5, 2018
9.8K
相关概念视频
01:27CNS Depressants: Alcohol and Nicotine
256
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
256
01:20Antiepileptic Drugs: Potassium Channel Activators
215
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
215
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
465
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
465
01:14Antiepileptic Drugs: Glutamate Antagonists
426
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
426